摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one | 1423027-37-5

中文名称
——
中文别名
——
英文名称
7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one
英文别名
5H,6H,7H,8H-imidazo[1,2-a]pyrazin-6-one;7,8-dihydro-5H-imidazo[1,2-a]pyrazin-6-one
7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one化学式
CAS
1423027-37-5
化学式
C6H7N3O
mdl
MFCD22741277
分子量
137.141
InChiKey
OZEDEFOLUBDEFN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.9
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    46.9
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE
    申请人:SUMITOMO DAINIPPON PHARMA CO., LTD.
    公开号:US20210387967A1
    公开(公告)日:2021-12-16
    Provided is a 2-heteroaryl aminoquinazolinone derivative, which is a compound represented by formula (1): or a pharmaceutically acceptable salt thereof wherein X 1 represents CR 1 or N, X 2 represents CR 2 or N, X 3 represents CR 3 or N, X 4 represents CR 4 or N, Y represents optionally substituted C 1-6 alkyl, an optionally substituted C 3-10 alicyclic group, an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, optionally substituted C 6-10 aryl, or optionally substituted 5- to 10-membered heteroaryl, Z represents optionally substituted 6- to 10-membered heteroaryl, and R 1 , R 2 , R 3 , and R 4 each independently represent a hydrogen atom, halogen, cyano, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkoxy, or the like.
    提供了一种2-杂环芳基喹唑啉酮衍生物,该化合物由式(1)表示:或其药学上可接受的盐其中X1代表CR1或N,X2代表CR2或N,X3代表CR3或N,X4代表CR4或N,Y代表可选择取代的C1-6烷基,可选择取代的C3-10脂环基,可选择取代的含氮非芳基杂环的4-至10-成员环,可选择取代的C6-10芳基,或可选择取代的5-至10-成员杂环芳基,Z代表可选择取代的6-至10-成员杂环芳基,R1、R2、R3和R4各自独立地代表氢原子、卤素、基、可选择取代的C1-6烷基、可选择取代的C1-6甲氧基等。
  • Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors
    申请人:Mansour Suhayl Tarek
    公开号:US20060276445A1
    公开(公告)日:2006-12-07
    This invention relates to certain bicyclic 6-alkylidene penems which act as a inhibitor of class-D enzymes. β-Lactamases hydrolyze β-lactam antibiotics, and as such serve as the primary cause of bacterial resistance. The compounds of the present invention when combined with β-lactam antibiotics will provide an effective treatment against life threatening bacterial infections. In accordance with the present invention there are provided compounds of general formula I or a pharmaceutically acceptable salt or in vivo hydrolyzable ester R 5 thereof: wherein: One of A and B denotes hydrogen and the other an optionally substituted fused bicyclic heteroaryl group; and X═O or S.
    这项发明涉及某些具有双环6-烷基亚烯基青霉素结构的化合物,其作为D类酶的抑制剂。β-内酰胺酶解β-内酰胺类抗生素,因此是细菌耐药的主要原因。本发明的化合物与β-内酰胺类抗生素结合后,将提供一种有效的治疗方法,用于治疗威胁生命的细菌感染。根据本发明,提供了一般式I的化合物,或其药学上可接受的盐或体内可解的酯R5:其中:A和B中的一个表示氢,另一个表示可选择取代的融合双环杂环芳基团;X=O或S。
  • [EN] BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS<br/>[FR] PENEMES 6-ALKYLIDENE BICYCLIQUES UTILISES EN TANT QU'INHIBITEURS DE ss-LACTAMASES
    申请人:WYETH CORP
    公开号:WO2003093279A1
    公开(公告)日:2003-11-13
    The present invention provides a compound of Formula (I), pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.
    本发明提供了一种化合物(I)的配方、药物组合物以及其用于治疗患有细菌感染或疾病的患者的用途。
  • 2-AMINOQUINAZOLINONE DERIVATIVE
    申请人:SUMITOMO DAINIPPON PHARMA CO., LTD.
    公开号:US20210380598A1
    公开(公告)日:2021-12-09
    The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1) [wherein X 1 represents CR or N, X 2 represents CR 2 or N, X 3 represents CR 3 or N, Y represents an optionally substituted C 6-10 aryl or optionally substituted 6 to 10-membered heteroaryl, Z represents an optionally substituted C 6-10 aryl, R A represents a hydrogen atom, halogen, cyano, optionally substituted C 1-6 alkyl sulfonyl, optionally substituted C 1-6 alkyl, or optionally substituted C 1-6 alkoxy, and R 1 , R 2 , and R 3 independently represent a hydrogen atom, halogen, optionally substituted C 1-6 alkyl, or optionally substituted C 1-6 alkoxy] or a pharmaceutically acceptable salt thereof.
    本发明提供了一种2-氨基喹唑啉酮衍生物。本发明是一种化合物,由式(1)表示[其中X1表示CR或N,X2表示CR2或N,X3表示CR3或N,Y表示可选取代的C6-10芳基或可选取代的6到10元杂环芳基,Z表示可选取代的C6-10芳基,RA表示氢原子,卤素,基,可选取代的C1-6烷基磺酰基,可选取代的C1-6烷基或可选取代的C1-6烷氧基,R1、R2和R3独立地表示氢原子,卤素,可选取代的C1-6烷基或可选取代的C1-6烷氧基]或其药学上可接受的盐。
  • Bicyclic 5-alkylidene-penems as beta lactamases inhibitors
    申请人:Wyeth
    公开号:US20040077622A1
    公开(公告)日:2004-04-22
    The present invention provides a compound of formula 1, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof. 1
    本发明提供了一种化合物1,其制备药物组合物并用于治疗需要治疗细菌感染或疾病的患者。
查看更多

同类化合物

脱氧助间型霉素 叔-丁基3-溴-8,9-二氢-5H-咪唑并[1,2-D][1,4]二氮杂卓-7(6H)-甲酸基酯 化合物RK-33 8-叔-丁基1-乙基6,7-二氢-5H-咪唑并[1,5-A][1,4]二氮杂卓-1,8(9H)-二甲酸基酯 8-(叔丁氧羰基)-6,7,8,9-四氢-5H-咪唑并[1,5-A][1,4]二氮杂-1-羧酸 6-羟基-4,5,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-8(1H)-酮 5-(8-羟基-7,8-二氢-4H-咪唑并[5,4-d][1,3]二氮杂卓-3-基)-3-(羟基甲基)环戊-3-烯-1,2-二醇 4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮 3-[(2-羟基乙氧基)甲基]-3,4,7,8-四氢咪唑并[4,5-d][1,3]二氮杂卓-8-醇 1H-咪唑并[1,5-d〕〔1,4]二氮杂(9CI) 1,4,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-5,8-二酮 (9ci)-1H-咪唑并[1,2-a][1,4]二氮杂卓 9H-imidazo[2,1-i]purin-8-one 3-(2-chlorobenzyl)-7-(4-methoxybenzyl)-3,7-dihydro-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one R-(-)-7-Methyl-5,6,7,8-tetrahydroimidazo<1,5-c>pyrimidin-5-on benzyl N-[(23R,52R)-52-amino-5,11,17,28,34,40,46,57-octamethyl-3,9,15,21,26,32,38,44,50,55-decaoxo-2,5,8,11,14,17,20,25,28,31,34,37,40,43,46,49,54,57,60,64-icosazanonacyclo[54.2.1.14,7.110,13.116,19.127,30.133,36.139,42.145,48]hexahexaconta-1(58),4(66),6,10(65),12,16(64),18,27(63),29,33(62),35,39(61),41,45(60),47,56(59)-hexadecaen-23-yl]carbamate tert-butyl (1-(1-(but-2-yn-1-yl)-4-methyl-7-oxo-6,7-dihydro-1H-imidazo[4,5-d]pyridazin-2-yl)piperidin-3-yl)carbamate 14-(7-(bromomethyl)-1H-imidazo[4,5-c]pyridin-4-yl)-14-azadispiro[5.0.57.36]pentadecane-13,15-dione cyclo-(-ImPyPyPy-(R)β-NHCbzγ-ImPyPyPy-(R)β-NHCbzγ-) benzyl N-[(23R,52R)-23-amino-5,11,17,28,34,40,46,57-octamethyl-3,9,15,21,26,32,38,44,50,55-decaoxo-2,5,8,11,14,17,20,25,28,31,34,37,40,43,46,49,54,57,60,61,64-henicosazanonacyclo[54.2.1.14,7.110,13.116,19.127,30.133,36.139,42.145,48]hexahexaconta-1(58),4(66),6,10(65),12,16(64),18,27(63),29,33(62),35,39(61),41,45(60),47,56(59)-hexadecaen-52-yl]carbamate 2-tert-butyldimethylsilyl-5-[(1S,2S)-2-dibenzylamino-1,4-dihydroxybutyl]-N,N-dimethylimidazole-1-sulfonamide 4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile benzyl N-[(23R,52R)-52-amino-5,11,17,28,34,40,46,57-octamethyl-3,9,15,21,26,32,38,44,50,55-decaoxo-2,5,8,11,14,17,20,25,28,31,34,37,40,43,46,49,54,57,60,61,64-henicosazanonacyclo[54.2.1.14,7.110,13.116,19.127,30.133,36.139,42.145,48]hexahexaconta-1(58),4(66),6,10(65),12,16(64),18,27(63),29,33(62),35,39(61),41,45(60),47,56(59)-hexadecaen-23-yl]carbamate (8R)-3-(p-Methoxybenzyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine 8H-Pyrazino[1,2-a]pyrimidine-8-carboxylic acid, 2-(2-aminoethyl)-4,6,7,9-tetrahydro-4-oxo-, 1,1-dimethylethyl ester 3,4,6,7-Tetrahydro-7-methyl-4-propylimidazo[4,5-e][1,4]diazepine-5,8-dione 1-methyl-1,2,3,4-tetrahydropyrido<3',2':4,5>imidazo<1,2-a>pyrimidin-2-one 5-(4H-1-piperazinyl)-11H-imidazo[1,2-c][1,3]benzodiazepine hydrobromide tert-butyl 7-(4-(benzyloxy)-2-oxopyridin-1(2H)-yl)-3,4-dihydropyrido[4',3':4,5]imidazo[1,2-a]pyridine-2(1H)-carboxylate N-(7H-Imidazo<1,5c><1,3>diazepin-5(6H)-yliden)-N'-<2-<(5-methyl-1H-imidazol-4-yl)methylthio>ethyl>harnstoff 1,2-Dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-e][1,4]diazepin-8-one 1-benzyl-5-hydroxy-4,5,6,7-tetrahydroimidazo<4,5-e><1,4>diazepin-8(1H)-one [5-(8-Hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-pentyl]-phosphonic acid dibenzyl ester 6,7-dihydro-3-<(2-hydroxyethoxy)methyl>imidazo<4,5-d><1,3>diazepin-8(3H)-one 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid monohydrochloride 1,6-dimethyl-1,4,6,7-tetrahydro-imidazo[4,5-b]pyridin-5-one 1-Benzyl-7,8-dihydro-1H,5H-imidazo<4,5-e><1,3>diazepine-4,6-dione methyl5H,6H,7H,8H,9H-imidazo[1,2-a][1,4]diazepine-6-carboxylatedihydrochloride 3-(2,4-difluorophenyl)-7-(4-methoxybenzyl)-3,7-dihydro-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one 3-(3,5-dimethyl-cyclohexyl)-1-methyl-6-methylsulfanyl-1H-[1,3,5]triazine-2,4-dione 3-{5-[2-(2-Trimethylsilanyl-ethoxymethyl)-2H-tetrazol-5-yl]-pentyl}-3,6,7,8-tetrahydro-imidazo[4,5-d][1,3]diazepin-8-ol N-{4-[(8-cyclohexyl-2,8-diazaspiro[4.5]dec-2-yl)methyl]benzyl}-2-(1H-imidazol-4-yl)-N-(1H-imidazol-2-ylmethyl)ethanamine 4-Fluoro-3-[2-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-benzoic acid methyl ester (8S)-3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-5-methylimidazo<4,5-d><1,3>diazepin-8-ol 6,7-dihydro-3-<<2-(p-toluoyloxy)ethoxy>methyl>imidazo<4,5-d><1,3>diazepin-8(3H)-one 3,4-dibenzyl-4,5,7,8-tetrahydro-6-hydroxy-6H-imidazo[4,5-e][1,4]diazepine-5,8-dione